DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

ABSTRACT: Background: Biomarkers predicting response to bevacizumab in breast cancer are still missing. Since epigenetic modifications can contribute to an aberrant regulation of angiogenesis and treatment resistance, we investigated the influence of DNA methylation patterns on bevacizumab efficacy. Methods: Genome-wide methylation profiling using the Illumina Infinium HumanMethylation450 BeadChip was performed in archival FFPE specimens of 36 patients with HER2-negative metastatic breast cancer treated with chemotherapy in combination with bevacizumab as first-line therapy (learning set). Based on objective response and progression-free survival (PFS) and considering ER expression, patients were divided in responders (R) and non-responders (NR). Significantly differentia

SUBMITTER: Gampenrieder SP 

PROVIDER: S-EPMC5928889 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature